Life sciences in Canada: new frontiers, new strategies | Torys LLP

Life sciences in Canada: new frontiers, new strategies

How do life sciences industry players and investors on both sides of the Canada-U.S. border navigate an ever-changing ecosystem? In this series, we discuss what’s next for this rapidly transforming sector.

Featured video: Health Canada medical device enforcement issues

Canada applies a lifecycle approach to the regulation of medical devices, with Health Canada holding broad enforcement powers. So, how do manufacturers ensure they follow best practices for post-market surveillance?

Yael Bienenstock, Teresa Reguly and Grant Worden share how to navigate an ongoing relationship with regulators, including:

Key compliance considerations
Health Canada enforcement actions
The judicial review process

Click here for a transcript of this video.

Also in this series

Medical device recalls and product corrections

Can the recall of a medical device in Canada affect a manufacturers operation elsewhere? And how does Canada's recall process differ from other jurisdictions? Find out here.

Medical device domain names, brands and patents

How can French language laws affect your medical device success in Canada, and can you repurpose existing patents? We answer key branding and patent questions.

Lessons learned from COVID-era medical device regulation

COVID-19 changed how Canada approaches medical device approval and regulation. Learn what changes were implemented, and which are here to stay.

What to know about the reimbursement and procurement of medical devices in Canada

In Part 4 of our series, we explore how medical devices procured and reimbursed in Canada, including what the competitive process looks like.

How to structure your medical device business

In Part 3 of our series, we look at common structuring questions such as whether you need to be incorporated in Canada, where should directors be based, and more.

Regulatory rules for selling a medical device in Canada

In Part 2 of our series, we walk you through key legal considerations to keep in mind when selling a medical device in Canada.

The Canadian landscape

What makes Canada’s regulation of medical devices unique from other countries? Find out in the first video in our series on medical devices in Canada.

Webinars

The future of product liability claims: is the MDL model coming to Canada?

Our panel will discuss where these developments may lead, issues related to simultaneous mass tort and class action litigation, and what impact it may all have on litigation strategy.

The price is right: where is drug pricing headed in Canada?

Our team will discuss emerging trends in drug pricing—including shifting dynamics between Canada’s drug pricing regulator, the PMPRB, and Canadian courts—and what the potential implications are for both regulatory, litigation and broader business strategies for companies in the life sciences sector.

Centralized procurement takes centre stage

This session will discuss the changing landscape for procurement in Canada as more governments and organizations move towards centralized procurement and other strategic issues for life sciences companies.

What’s on your privacy radar?: trends and developments in life sciences

Join our team for a conversation on recent federal and provincial regulatory changes and case law developments—from biometrics and data governance to privacy breach response and the latest class action trends.

Top 10 and beyond: what’s next for Canadian life sciences

With a range of changes underway for Canadian pharmaceutical, medical device, biotech and other life sciences companies, we explore the top 10 developments in these spaces and their impact on business.

Recent publications

Lab tested, lawyer approved: Strategies for life science leasing

What should parties be thinking about when embarking on leasing real estate for the unique needs of the life sciences sector?

Did the CRA shred its old SR&ED policy on eligibility of work?

There’s a new framework for businesses to use when assessing research and development expenditures for SR&ED eligibility, but what really changed?

Update on Canada’s finalized framework for supplemented foods and new labelling rules for natural health products

Watch Guy Berman and Janan Paskaran explain how private equity sponsors can take a PE-specific approach when preparing to IPO.

Subscribe and stay informed

Stay in the know. Get the latest commentary, updates and insights for business from Torys.